Ikena Oncology, Inc.

NasdaqGM:IKNA Stock Report

Market Cap: US$66.1m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Ikena Oncology Future Growth

Future criteria checks 0/6

Ikena Oncology's earnings are forecast to decline at 37.1% per annum. EPS is expected to decline by 14.5% per annum.

Key information

-37.1%

Earnings growth rate

-14.50%

EPS growth rate

Pharmaceuticals earnings growth14.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated24 Jul 2025

Recent future growth updates

Recent updates

Analysis Article • Jun 01

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Key Insights Ikena Oncology to hold its Annual General Meeting on 7th of June Salary of US$569.0k is part of CEO Mark...
Analysis Article • Nov 10

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 15

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Today is shaping up negative for Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders, with the analysts delivering a...
Analysis Article • May 20

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

Shareholders in Ikena Oncology, Inc. ( NASDAQ:IKNA ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Apr 29

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 06

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 06

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 23

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Mar 21

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ikena Oncology, Inc. ( NASDAQ:IKNA ) just released its annual report and things are looking bullish. The results were...
Analysis Article • Feb 19

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 02

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 13

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Earnings and Revenue Growth Forecasts

NasdaqGM:IKNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-80N/AN/A2
12/31/2026N/A-49N/AN/A2
12/31/2025N/A-30N/AN/A2
6/30/2025N/A-31-29-29N/A
3/31/2025N/A-42-38-38N/A
12/31/2024N/A-49-46-46N/A
9/30/20241-60-62-62N/A
6/30/20242-67-73-73N/A
3/31/20244-70-79-78N/A
12/31/20239-68-80-80N/A
9/30/202314-63-76-76N/A
6/30/202319-63-74-73N/A
3/31/202318-66-76-74N/A
12/31/202216-69-76-74N/A
9/30/202230-52-72-70N/A
6/30/202228-49-71-71N/A
3/31/202231-41-68-67N/A
12/31/202131-34-62-60N/A
9/30/202111-63-61-59N/A
6/30/202110-55-51-49N/A
3/31/20219-47-43-41N/A
12/31/20209-44-39-38N/A
9/30/202012-23-34-33N/A
12/31/201914-174848N/A
12/31/20181-41N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IKNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IKNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IKNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IKNA's revenue is forecast to grow faster than the US market.

High Growth Revenue: IKNA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IKNA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/25 00:21
End of Day Share Price 2025/07/25 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ikena Oncology, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David NierengartenWedbush Securities Inc.
Matthew PhippsWilliam Blair & Company L.L.C.